Illustration for: Radical Numerics Raises $50M to Build AI That Simulates Biology

Radical Numerics Raises $50M to Build AI That Simulates Biology

Radical Numerics raised $50 million led by Emergence Capital to build AI models that simulate biological systems -- a bet that foundation-model techniques can model cells and living processes the way world models simulate physics. It's part of a clear 2026 wave of capital flowing toward AI-for-science applied to specific scientific domains.

By the Numbers

$50M
Raised
Emergence Capital
Lead
Biological simulation
Focus
TC
By the Funding Desk
Edited by Trace Cohen · Early-stage VC & angel · Founder, New York Venture Partners
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

AI-for-biology is maturing from hype into funded products aimed at drug discovery and life-sciences R&D

2

Domain-specific simulation models are where 'AI scientist' claims get tested against real, measurable utility

TC

The VC Read · Trace's Take

Trace Cohen

World models for physics, simulation models for biology -- 2026's frontier theme is teaching AI to model reality, not just text. Radical Numerics is a clean expression of that thesis pointed at the slowest, most expensive lab work in the economy. The bar to clear is the same one LifeSciBench just exposed: simulate to augment the scientist, don't over-claim autonomous discovery. Get the framing right and this is a durable category; get it wrong and it's another computational-biology cautionary tale.

Analysis

Radical Numerics raised $50 million in a round led by Emergence Capital to develop AI models that simulate biological systems. The company is applying foundation-model methods to the problem of modeling cells, proteins, and living processes -- the biological analogue of the 'world models' that simulate physical environments for robotics.

The round sits within a broader 2026 surge of capital into AI-for-science, where investors are funding teams that aim to compress the slow, expensive cycle of biological experimentation with predictive simulation. If the models work, they could accelerate drug discovery and life-sciences research; if they don't, they join a long history of computational-biology bets that over-promised.

For builders, the honest framing matters: simulation models are powerful accelerants for scientists, not replacements, and the credible pitch is augmenting wet-lab work with faster in-silico iteration rather than claiming autonomous discovery.

ShareXLinkedInEmail

Key Sources

2 sources

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.